Literature DB >> 15356120

A dual role of IFN-alpha in the balance between proliferation and death of human CD4+ T lymphocytes during primary response.

Elisabetta Dondi1, Gaël Roué, Victor J Yuste, Santos A Susin, Sandra Pellegrini.   

Abstract

Type I IFNs (IFN-alphabeta) enhance immune responses, notably T cell-mediated responses, in part by promoting the functional activities of dendritic cells. In this study, we analyzed the direct impact of IFN-alpha on proliferative and apoptotic signals upon in vitro activation of human naive CD4+ T lymphocytes. We demonstrate that IFN-alpha protects T cells from the intrinsic mitochondrial-dependent apoptosis early upon TCR/CD28 activation. IFN-alpha acts by delaying entry of cells into the G1 phase of the cell cycle, as well as by increasing Bcl-2 and limiting Bax activation. Later, upon activation, T cells that were exposed to IFN-alpha showed increased levels of surface Fas associated with partially processed caspase-8, a key component of the extrinsic apoptotic pathway. Caspase-8 processing was augmented furthermore by Fas ligation. Overall, these findings support a model whereby IFN-alpha favors an enhanced clonal expansion, yet it sensitizes cells to the Ag-induced cell death occurring at the end of an immune response. These observations point to a complex role of type I IFN in regulating the magnitude of proliferation and survival of naive CD4+ T cells during primary response and underline how crucial could be the timing of exposure to this cytokine. Copyright 2004 The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356120     DOI: 10.4049/jimmunol.173.6.3740

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients.

Authors:  Jean-Philippe Herbeuval; Jakob Nilsson; Adriano Boasso; Andrew W Hardy; Michael J Kruhlak; Stephanie A Anderson; Matthew J Dolan; Michel Dy; Jan Andersson; Gene M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Control of type I interferon-induced cell death by Orai1-mediated calcium entry in T cells.

Authors:  Chanyu Yue; Jonathan Soboloff; Ana M Gamero
Journal:  J Biol Chem       Date:  2011-12-05       Impact factor: 5.157

Review 3.  HIV-1 immunopathogenesis: how good interferon turns bad.

Authors:  Jean-Philippe Herbeuval; Gene M Shearer
Journal:  Clin Immunol       Date:  2006-11-16       Impact factor: 3.969

4.  Alpha and lambda interferon together mediate suppression of CD4 T cells induced by respiratory syncytial virus.

Authors:  Bo Chi; Harold L Dickensheets; Kirsten M Spann; Marc A Alston; Cindy Luongo; Laure Dumoutier; Jiaying Huang; Jean-Christophe Renauld; Sergei V Kotenko; Mario Roederer; Judy A Beeler; Raymond P Donnelly; Peter L Collins; Ronald L Rabin
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

5.  Receptor density is key to the alpha2/beta interferon differential activities.

Authors:  Ignacio Moraga; Daniel Harari; Gideon Schreiber; Gilles Uzé; Sandra Pellegrini
Journal:  Mol Cell Biol       Date:  2009-06-29       Impact factor: 4.272

Review 6.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

7.  CD57 ratio as a convenient and useful immunological and prognostic parameter for stage IV carcinoma.

Authors:  Junji Akagi; Hideo Baba
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

8.  Terminally differentiated CD8+ T cells and CD57-FOXP3+CD8+ T cells are highly associated with the efficacy of immunotherapy using activated autologous lymphocytes.

Authors:  Junji Akagi; Hideo Baba; Teruaki Sekine; Kenji Ogawa
Journal:  Oncol Lett       Date:  2018-04-17       Impact factor: 2.967

9.  Immuno-modulatory strategies for reduction of HIV reservoir cells.

Authors:  H T Banks; Kevin B Flores; Shuhua Hu; Eric Rosenberg; Maria Buzon; Xu Yu; Matthias Lichterfeld
Journal:  J Theor Biol       Date:  2015-02-17       Impact factor: 2.691

10.  Impaired interferon signaling is a common immune defect in human cancer.

Authors:  Rebecca J Critchley-Thorne; Diana L Simons; Ning Yan; Andrea K Miyahira; Frederick M Dirbas; Denise L Johnson; Susan M Swetter; Robert W Carlson; George A Fisher; Albert Koong; Susan Holmes; Peter P Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-18       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.